“Spesolimab Decreases Generalized Pustular Psoriasis (GPP) Body Surface Area (BSA) over Time in Patients Switching from Conventional Systemic Treatments: Results from the EFFISAYIL® 2 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s488, https://doi.org/10.25251/skin.8.supp.488.